Gut microbiome study in liver cancer patients on combination therapy
Part of Cancer, Digestive system clinical trials.
This study looks at how the bacteria in your gut (microbiome) might affect treatment for liver cancer. It tests a combination of targeted therapy and immunotherapy, which are already approved for liver cancer. The goal is to see if gut bacteria can predict how well the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have been diagnosed with liver cancer (HCC) that cannot be removed by surgery and is at stage B or C (BCLC).
- You have not had any systemic (body-wide) treatment for liver cancer before.
- You are planned to receive a type of targeted drug (anti-angiogenic) combined with an immunotherapy drug (immune checkpoint inhibitor).
- Your liver function is good (Child-Pugh A) and you have at least one measurable tumor.
- You are physically active (ECOG score 0-1) and do not have serious infections (like active hepatitis B or C, or HIV).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the bacteria in your gut (microbiome) affect liver cancer treatment. It aims to learn if certain gut bacteria can predict how well the combination of targeted therapy and immunotherapy works.
This trial studies how the gut (your digestive system) affects how well immunotherapy works for advanced liver cancer. You'll have a colonoscopy (a test to look inside your bowel) and provide samples, which could help doctors improve treatment for you and others.
This study tests a combination of liver-directed chemotherapy (given through a small tube into the liver artery), targeted therapy, and an immunotherapy drug (a PD-1 inhibitor) to help prevent liver cancer from coming back after surgery. It is for people whose tumor showed microvascular invasion, which raises the risk of recurrence.
This trial tests whether changing the bacteria in your gut (with a probiotic) can help your current immunotherapy work better if your liver cancer has been growing. It's for people with advanced liver cancer who will continue their same immunotherapy despite the cancer progressing.
This trial studies whether a fecal microbiota transfer (a “gut bacteria transfer” from a donor) can help liver cancer patients overcome resistance to atezolizumab and bevacizumab. It aims to improve how well the standard medicines control the cancer.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.